Novavax (NVAX) Cash & Equivalents Growth (3y) (2013 - 2026)
Powered by 
Analysis
Novavax (NVAX) Cash & Equivalents Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | -15.41% |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 8.23% |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 47.78% |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | -23.18% |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 14.34% |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 37.45% |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | -27.97% |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -3.85% |
| 10 | Novavax | 1.67 Bn | 951.85 Mn | 42.45 Mn | -27.66% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -27.66% |
| Mar 31, 2026 | -28.50% |
| Dec 31, 2025 | -43.54% |
| Sep 30, 2025 | -40.63% |
| Jun 30, 2025 | -43.08% |
| Mar 31, 2025 | -44.86% |
| Dec 31, 2024 | -29.53% |
| Sep 30, 2024 | -33.34% |
| Jun 30, 2024 | -31.05% |
| Mar 31, 2024 | -37.78% |
| Dec 31, 2023 | 0.90% |
| Sep 30, 2023 | 24.90% |
| Jun 30, 2023 | 6.03% |
| Mar 31, 2023 | 51.46% |
| Dec 31, 2022 | 156.93% |
| Sep 30, 2022 | 162.05% |
| Jun 30, 2022 | 167.34% |
| Mar 31, 2022 | 152.39% |
| Dec 31, 2021 | 178.48% |
| Sep 30, 2021 | 224.87% |